UK Community Advisory Board (UK-CAB)

UK-CAB 81: ViiV healthcare, Monkeypox virus update

Date: Friday 22 July 2022

Venue: Room 101 Russell Square Campus, Birkbeck College, London WC1B 5EA


Chair: Alex Sparrowhawk
09.30-09.45 Arrival, tea and refreshments, expenses
09:45- 10.00 Welcome and introductions
UK-CAB updates
Company pre-meeting
10:00-11:30  Company meeting: ViiV Healthcare
11:30-11:45 BREAK
11.45-12.30 Monkeypox virus – personal story: Harun Tulunay
12.45-14.00 LUNCH
14:00-15:00 Monkeypox Virus update 
15:00-15:30 FTC updates 
15:30-15:45 BREAK
15:45 -16.30 Members Updates
Meeting reflection
16.30 – 17:00 Any other business
Meeting close

Presentations and meeting report:

Monkeypox virus – personal story: Harun Tulunay
Monkeypox virus update
Fast Track Cities update
Meeting report (to follow)

Background reading

MonkeyPox Virus:

Monkeypox: Q&A factsheet | HIV i-Base
What is monkeypox? Monkeypox is an infection caused by the monkeypox virus (MPV or MPxV). MPX is usually rarely seen in the UK. However, since May 2022, more than 900 cases of MPX have been reported in the UK. Nearly all cases are in gay and bisexual men.

Consensus statement on response to the Monkeypox outbreak
This is a letter including a consensus statement on monkeypox was sent to Steve Barclay, Secretary of State for Health and Social Care, Amanda Pritchard, CEO at NHS England, Jenny Harries OBE, CEO of the UK Health Security Agency, Professor Sir Andrew Pollard, KB Chair, UK Joint Committee on Vaccination and Immunisation. The statement was drafted by the British Association for Sexual Health and HIV (BASHH), Association of Directors of Public Health, Terrence Higgins Trust, National AIDS Trust, British HIV Association, LGBT Foundation, PrEPster, i-base and UK-CAB.

Monkeypox outbreak: Update and further information | HTB | HIV i-Base
This issue of HTB includes several articles about the recent outbreak of monkeypox (MPX). WHO has already confirmed over 900 cases in 28 countries where MPX is not endemic. The UK has so far reported the highest number of cases (220), followed by Spain (135) and Portugal (100). These are nearly all in, or connected to, London, Madrid and Portugal.

ViiV Healthcare:
NICE approves long-acting cabotegravir and rilpivirine … – i-Base
Long-acting cabotegravir plus rilpivirine (CAB/RPV-LA) currently involves oral tablets for the first month, higher dose first injections, and then two separate intramuscular injections every two months. Injections need to be given by a health professional.

NHS Scotland approves long-acting cabotegravir and rilpivirine … – i-Base
The list price for the two-monthly doses of CAB-LA (Vocabria) and RPV-LA (Rekambys) is approximately £1200 and £440 respectively: just short of £10,000 for a year. The lower negotiated price as part of a Patient Access Scheme (PAS) has not been released – but ICER/QALY models and base-case scenarios are referenced in the detailed SMA advice. [2]

Long-acting cabotegravir injections are effective as HIV … – HIV i-Base
Overall, CAB-LA was superior to oral TDF/FTC, with the better results likely due to suboptimal adherence to oral TDF/FTC. However, in the context of perfect adherence, TDF/FTC is already effectively 100%, so further analyses are needed on drug resistance and drug levels to understand cause of the five infections linked to CAB-LA. Either way …

FDA decision on long-acting cabotegravir/rilpivirine … – HIV i-Base
Cabotegravir is an integrase inhibitor developed by ViiV Healthcare and rilpivirine is an NNRTI developed by Janssen Sciences. Development of CAB/RPV long-acting combination is led by ViiV, with the trade name Cabenuva in the US and Vocabria in the EU. Comment

Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial … – i-Base
CAB-LA/RPV-LA was approved by NHS Scotland on 11 October and by NHS England on 18 November 2021. Reference Teichner P et al. Outcomes for participants during long-term follow-up after discontinuation of cabotegravir + rilpivirine long-acting in the phase III/IIIb clinical trials.

ViiV licenses long-acting cabotegravir (CAB-LA) for generic access
ViiV Healthcare. ViiV Healthcare open to voluntary licensing as part of approach to enable greater access to cabotegravir la for prep in low- and middle-income countries. (March 2022)


  • Since 2011, i-Base provide admin support to the UK-CAB. Other costs are covered by grants to the UK-CAB. This includes support from drug companies for meetings.
  • Training courses are funded by specific grants, including from the Lottery Fund.
  • From 2008-2011 the CAB was supported by the Monument Trust. This allowed us to employ a part-time administrator.
  • From 2002 to 2008, running costs for the UK-CAB were supported by i-Base. Drug companies funding meeting costs.

We have always asked HIV drug companies to support the direct costs for UK-CAB meetings.

This covers travel and accommodation for members coming from out of London. It also covers the cost of catering. This industry funding helps support the CAB as a national project. A list of supporting companies since the UK-CAB was established in 2002 and from the most recent years is included below. 3

The UK-CAB membership and Steering Group decides the content for all meetings.

Meetings with a drug company covers their current products and future research. The decision for which companies to invite and the agenda for these meetings is made by the UK-CAB.

We also ask other researchers to involve the UK-CAB in planning studies and ongoing research. We ask that community involvement in research be included in the budget of grant proposals so that some of the CAB work can be supported in this way by independent research.